Clinical Data Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study BioSpaceA single 1-mg/kg dose of Eli Lilly's base editor can lower LDL cholesterol levels by 62% in patients with a heritable form of hypercholesterolemia.CardiovascularRead full story pharminent May 26, 2026 (Last updated: May 26, 2026) BioSpace A single 1-mg/kg dose of Eli Lilly’s base editor can lower LDL cholesterol levels by 62% in patients with a heritable form of hypercholesterolemia. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRCNext: Arthrosi drug trial in gout delivers for new owner Sobi Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
